Daiwa Securities Group’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-225
Closed -$29K 1339
2025
Q2
$29K Buy
225
+15
+7% +$1.56K ﹤0.01% 1088
2025
Q1
$19K Hold
210
﹤0.01% 1071
2024
Q4
$18K Sell
210
-27
-11% -$2.47K ﹤0.01% 1087
2024
Q3
$22K Hold
237
﹤0.01% 1095
2024
Q2
$26K Sell
237
-4
-2% -$400 ﹤0.01% 1122
2024
Q1
$23K Hold
241
﹤0.01% 1132
2023
Q4
$22K Hold
241
﹤0.01% 1116
2023
Q3
$12K Hold
241
﹤0.01% 1117
2023
Q2
$15K Hold
241
﹤0.01% 1120
2023
Q1
$11K Hold
241
﹤0.01% 1105
2022
Q4
$11K Buy
241
+19
+9% +$911 ﹤0.01% 1108
2022
Q3
$15K Hold
222
﹤0.01% 1107
2022
Q2
$11K Buy
222
+50
+29% +$2.93K ﹤0.01% 1136
2022
Q1
$11K Hold
172
﹤0.01% 1132
2021
Q4
$18K Sell
172
-29
-14% -$3.03K ﹤0.01% 1121
2021
Q3
$21K Buy
201
+86
+75% +$8.01K ﹤0.01% 1099
2021
Q2
$10K Hold
115
﹤0.01% 1046
2021
Q1
$11K Buy
115
+10
+10% +$998 ﹤0.01% 1041
2020
Q4
$12K Sell
105
-204
-66% -$21.5K ﹤0.01% 1006
2020
Q3
$29K Buy
309
+8
+3% +$616 ﹤0.01% 966
2020
Q2
$18K Hold
301
﹤0.01% 1026
2020
Q1
$18K Buy
301
+23
+8% +$1.48K ﹤0.01% 1011
2019
Q4
$22K Sell
278
-35
-11% -$2.62K ﹤0.01% 1005
2019
Q3
$23K Buy
313
+6
+2% +$519 ﹤0.01% 990
2019
Q2
$29K Buy
307
+27
+10% +$2.23K ﹤0.01% 991
2019
Q1
$22K Buy
280
+40
+17% +$2.96K ﹤0.01% 987
2018
Q4
$13K Hold
240
﹤0.01% 986
2018
Q3
$19K Hold
240
﹤0.01% 1004
2018
Q2
$15K Hold
240
﹤0.01% 1022
2018
Q1
$22K Buy
+240
New +$20.7K ﹤0.01% 988

Other funds holding BPMC

Daiwa Securities Group's BPMC Position: Q3 2025 in Review

Daiwa Securities Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 225 shares — an estimated $29K sold.

Daiwa Securities Group first reported a position in BPMC in Q1 2018 and held it in 30 quarters. The position peaked at $29K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Daiwa Securities Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Daiwa Securities Group sold 225 Blueprint Medicines shares in Q3 2025, an estimated $29K.
  • Daiwa Securities Group first reported a position in Blueprint Medicines in Q1 2018 and held it in 30 quarters.
  • Daiwa Securities Group's Blueprint Medicines position peaked at $29K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Daiwa Securities Group's 13F filing for Q3 2025, filed 14 Nov 2025.